Nuklearmedizin - NuclearMedicine, Table of Contents Nuklearmedizin 2002; 41(06): 230-232DOI: 10.1055/s-0038-1625293 Editorial Schattauer GmbH Quo vadis Radioimmun- und Radiopeptidtherapie? Welche Rolle spielen sie künftig im klinischen Alltag?[*] Recommend Article Abstract Buy Article Full Text References Literatur 1 Behr TM, Béhé M, Becker W. Radioimmuntherapie hämatologischer und solider Neoplasien. In: Kneba M, Dreger P, Pantel K. (Hsg). Anti-körpertherapie in der Hämatologie und Onkologie. Bremen, London, Boston: UNI-MED Science; 2001: 157-75. 2 Behr TM, Béhé M, Kluge G. et al. Nephrotoxi-city versus anti-tumour efficacy in radiopeptide therapy: facts and myths about the Scylla and Charybdis. Eur J Nucl Med 2002; 29: 277-9. 3 Behr TM, Goldenberg DM, Becker WS. Radioimmunotherapy of solid tumors: a review “Of Mice and Men“. Hybridoma 1997; 16: 101-7. 4 Behr TM, Gotthardt M, Barth A. et al. Imaging tumors with peptide-based radioligands. Q J Nucl Med 2001; 45: 189-200. 5 Behr TM. Do we need myeloablative, high-dose therapy in radioimmunotherapy of nonHodgkin’s lymphoma?. Eur J Nucl Med. 2002 in press. 6 Bell E, Grünwald F. Radiojodtherapie bei benignen und malignen Schilddrüsenerkrankungen. Berlin, Heidelberg, New York: Springer; 1999 7 DeVita Jr VT, Hellman S, Rosenberg SA. (eds). Cancer – Principles and practice of oncology. Philadelphia, New York: Lippincott – Raven; 1997. 5th ed. 8 Feld M, DeRoo M. Geschichte der Nuklearmedizin in Europa. Stuttgart, New York: Schattauer; 2000 9 Goldenberg DM, DeLand F, Kim E. et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978; 298: 1384-6. 10 Goldenberg DM. Targeted therapy of cancer with radiolabeled antibodies. J Nucl Med 2002; 43: 693-713. 11 Gopal AK, Rajendran JG, Petersdorf SH. et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002; 99: 3158-62. 12 Waldherr C, Pless M, Maecke HR. et al. The clinical value of [90Y-DOTA]-D-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001; 12: 941-5.
